Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nutrients ; 15(24)2023 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-38140378

RESUMO

Lacticaseibacillus paracasei strain Shirota (LcS) modulates psychological homeostasis via the gut-brain axis. To explore the possible efficacy of LcS for improving daytime performance, we conducted a double-blind, randomized, crossover, placebo-controlled study of 12 healthy office workers with sleep complaints. The participants received fermented milk containing viable LcS (daily intake of 1 × 1011 colony-forming units) and non-fermented placebo milk, each for a 4-week period. In the last week of each period, the participants underwent assessments of their subjective mood and measurements of physiological state indicators via an electroencephalogram (EEG) and heart rate variability in the morning and afternoon. The attention score in the afternoon as assessed by the visual analog scale was higher in the LcS intake period than in the placebo intake period (p = 0.041). Theta power on EEG measured at rest or during an auditory oddball task in the afternoon was significantly lower in the LcS period than in the placebo period (p = 0.025 and 0.009, respectively). The change rate of theta power was associated with the change in attention score. Treatment-associated changes were also observed in heart rate and the sympathetic nerve activity index. These results indicate that LcS has possible efficacy for improving daytime performance, supported by observations of the related physiological state indicators.


Assuntos
Lacticaseibacillus casei , Lacticaseibacillus paracasei , Probióticos , Animais , Humanos , Método Duplo-Cego , Eletroencefalografia , Leite , Estudos Cross-Over
2.
Appl Environ Microbiol ; 82(12): 3649-58, 2016 06 15.
Artigo em Inglês | MEDLINE | ID: mdl-27208120

RESUMO

UNLABELLED: Stress-induced abdominal dysfunction is an attractive target for probiotics. To investigate the effects of the probiotic Lactobacillus casei strain Shirota on abdominal dysfunction, a double-blind, placebo-controlled trial was conducted with healthy medical students undertaking an authorized nationwide examination for academic advancement. For 8 weeks, until the day before the examination, 23 and 24 subjects consumed an L. casei strain Shirota-fermented milk and a placebo milk daily, respectively. In addition to assessments of abdominal symptoms, psychophysical state, and salivary stress markers, gene expression changes in peripheral blood leukocytes and composition of the gut microbiota were analyzed using DNA microarray analysis and 16S rRNA gene amplicon sequence analysis, respectively, before and after the intervention. Stress-induced increases in a visual analog scale measuring feelings of stress, the total score of abdominal dysfunction, and the number of genes with changes in expression of more than 2-fold in leukocytes were significantly suppressed in the L. casei strain Shirota group compared with those in the placebo group. A significant increase in salivary cortisol levels before the examination was observed only in the placebo group. The administration of L. casei strain Shirota, but not placebo, significantly reduced gastrointestinal symptoms. Moreover, 16S rRNA gene amplicon sequencing demonstrated that the L. casei strain Shirota group had significantly higher numbers of species, a marker of the alpha-diversity index, in their gut microbiota and a significantly lower percentage of Bacteroidaceae than the placebo group. Our findings indicate that the daily consumption of probiotics, such as L. casei strain Shirota, preserves the diversity of the gut microbiota and may relieve stress-associated responses of abdominal dysfunction in healthy subjects exposed to stressful situations. IMPORTANCE: A novel clinical trial was conducted with healthy medical students under examination stress conditions. It was demonstrated that the daily consumption of lactic acid bacteria provided health benefits to prevent the onset of stress-associated abdominal symptoms and a good change of gut microbiota in healthy medical students.


Assuntos
Biota/efeitos dos fármacos , Trato Gastrointestinal/efeitos dos fármacos , Trato Gastrointestinal/microbiologia , Lacticaseibacillus casei/metabolismo , Leite/microbiologia , Probióticos/administração & dosagem , Estresse Fisiológico , Adulto , Animais , Análise por Conglomerados , DNA Bacteriano/química , DNA Bacteriano/genética , DNA Ribossômico/química , DNA Ribossômico/genética , Método Duplo-Cego , Feminino , Fermentação , Humanos , Masculino , Leite/metabolismo , Filogenia , Placebos/administração & dosagem , RNA Ribossômico 16S/genética , Análise de Sequência de DNA , Estudantes de Medicina , Resultado do Tratamento , Adulto Jovem
3.
Neurosci Lett ; 619: 114-20, 2016 Apr 21.
Artigo em Inglês | MEDLINE | ID: mdl-26971699

RESUMO

Intragastric (IG) administration of probiotic strain Lactobacillus casei Shirota (LcS) decreases the sympathetic nerve outflow of anesthetized rats in a tissue-specific manner. In the present study, we examined the effects of IG administration of LcS on sympathetic activation induced by an intracerebroventricular (ICV) injection of corticotrophin-releasing factor (CRF) and an intravenous (IV) injection of 2-deoxy-d-glucose (2DG) or interleukin (IL)-1ß in urethane-anesthetized rats. The IG administration of LcS differently affected the stimulatory responses of sympathetic nerve outflow to CRF. LcS suppressed the increase in splenic sympathetic nerve activity (Spleen-SNA), induced by central CRF, in a dose-dependent manner; however, it did not alter adrenal sympathetic nervous activity (ASNA). In contrast, LcS did not affect spleen-SNA and ASNA following an IV injection of IL-1ß. On the other hand, IG administration of LcS suppressed the activation of ASNA following an IV injection of 2DG. These findings suggest that the suppression of central CRF-induced sympathetic activation by LcS is tissue-specific. Moreover, it can suppress the 2DG-induced sympathetic activation. Furthermore, we found that stomach-specific vagotomy attenuates the suppressive effect of LcS on CRF-mediated spleen-SNA activation. Thus, the present study suggests that LcS administered to the stomach may act on the afferent vagal nerve and send afferent signals to the brain to regulate efferent SNA induced by sympathetic stimulators.


Assuntos
Hormônio Liberador da Corticotropina/farmacologia , Desoxiglucose/farmacologia , Lacticaseibacillus casei , Probióticos/farmacologia , Baço/inervação , Sistema Nervoso Simpático/fisiologia , Vias Aferentes/fisiologia , Anestésicos/farmacologia , Animais , Hormônio Liberador da Corticotropina/administração & dosagem , Desoxiglucose/administração & dosagem , Injeções Intravenosas , Injeções Intraventriculares , Interleucina-6/administração & dosagem , Interleucina-6/farmacologia , Masculino , Especificidade de Órgãos , Ratos Wistar , Estômago/inervação , Uretana/farmacologia , Vagotomia , Nervo Vago/fisiologia
4.
Intern Med ; 51(19): 2775-80, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23037473

RESUMO

A 34-year-old woman with bilateral pulmonary infiltrates was diagnosed with sarcoidosis. She refused corticosteroid treatment despite a worsening of the pulmonary infiltrate, and thereafter developed dyspnea following hemoptysis 6 years later. The upper lobe branches of the pulmonary artery were obstructed and the left main pulmonary artery was narrowed by mediastinal soft tissue, thus complications of granulomatous mediastinitis and fibrosing mediastinitis were suspected. The mediastinal soft tissue regressed, following the administration of corticosteroids, whereas the vascular obstruction and narrowing remained unchanged. Although the obstruction or stenosis of major pulmonary vessels is rare in sarcoidosis, such potential developments should be considered when mediastinal soft tissue appears in follow-up examinations.


Assuntos
Arteriopatias Oclusivas/etiologia , Arteriopatias Oclusivas/patologia , Pneumopatias/complicações , Pneumopatias/patologia , Artéria Pulmonar/patologia , Sarcoidose/complicações , Sarcoidose/patologia , Adulto , Arteriopatias Oclusivas/diagnóstico por imagem , Arteriopatias Oclusivas/tratamento farmacológico , Constrição Patológica , Feminino , Humanos , Pneumopatias/diagnóstico por imagem , Pneumopatias/tratamento farmacológico , Prednisolona/uso terapêutico , Artéria Pulmonar/diagnóstico por imagem , Sarcoidose/diagnóstico por imagem , Sarcoidose/tratamento farmacológico , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...